Ao-Lin Hsu, PhD

Associate Professor, Internal Medicine

University of Michigan

109 Zina Pitcher Place

2027 BSRB

Ann Arbor, MI 48109-2200


Ao-Lin Hsu, Ph.D., is an associate professor of Internal Medicine and Molecular & Integrative Physiology. He received his Ph.D. degree in medicinal chemistry from University of Kentucky, College of Pharmacy in December 2000. After postdoctoral studies in biochemistry and biophysics at University of California, San Francisco from 2001-2004, he joined the faculty of University of Michigan in fall 2004. His laboratory works on the regulation of longevity by Heat-shock transcription factor, the effect of dietary restriction on the rate of aging, and the development of drugs that affect the rate of aging. Dr. Hsu is a recipient of the Ellison Medical Foundation, New Scholar Award in Aging (2005-2009).

Published Articles:

HSF-1 regulators DDL-1/2 link insulin-like signaling to heat-shock responses and modulation of longevity

C. elegans SIRT6/7 homolog SIR-2.4 promotes DAF-16 relocalization and function during stress

Celecoxib extends C. elegans lifespan via inhibition of insulin-like signaling but not cyclooxygenase-2 activity

drr-2 encodes an eIF4H that acts downstream of TOR in diet-restriction-induced longevity of C. elegans

Areas of Interest

The Hsu laboratory studies genetics and cell biology of aging using C. elegans as a model organism.  Current projects have been focused on unraveling the role of Heat-shock Transcription Factor (HSF-1) in specifying longevity, stress resistance, and the onset of age-related neurodegenerative diseases. His group is particularly interested in the cross talks between the insulin signaling and HSF-1 pathway. Another research focus of his group is to study genes that are responsible for the longevity response to dietary restriction (DR). His group is currently interested in the role of protein translation initiation and S-adenosyl-methionine-dependent methylation in DR-mediated longevity extension.  Finally, his group is also working on developing new therapeutic agents that can delay the rate of aging using the C. elegans model.